Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 9/20 | 0.52 |
| ▸ | MMP2 | P08253 | 6/20 | 0.52 |
| ▸ | MMP14 | P50281 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29878255 | 1.00 | RAB9A (0.60) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL31092733 | 0.89 | RAB9A (0.57) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2580969 | 0.87 | KDM4E (0.52) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2321307 | 0.86 | XDH (0.48) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL29878461 | 0.85 | KDM4E (0.58) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2107136 | 0.85 | KDM4E (0.58) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2108919 | 0.85 | KDM4E (0.61) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL9081991 | 0.83 | KDM4E (0.59) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL7688984 | 0.83 | SRD5A2 (0.51) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3955334 | 0.82 | KDM4E (0.58) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725493-A2 | POLYCYCLIC COMPOUNDS FOR INHIBITING RNA HELICASE DHX33 AND USE THEREOF | Shenzhen Keye Life Technologies, Co., Ltd. (CN) | 2026-04-15 | — | — | EP | disclosed |
| CN-112661754-B | Polycyclic compound for inhibiting RNA helicase DHX33 | 成都开悦生命科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| US-20230146233-A1 | A CLASS OF POLYCYCLIC COMPOUNDS INHIBITING RNA HELICASE DHX33 AND THE APPLICATION THEREOF | SHENZHEN KEYE LIFE TECHNOLOGIES, CO., LTD (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230146233-A1 | A CLASS OF POLYCYCLIC COMPOUNDS INHIBITING RNA HELICASE DHX33 AND THE APPLICATION THEREOF | SHENZHEN KEYE LIFE TECHNOLOGIES, CO., LTD (CN) | 2023-05-11 | — | — | US | disclosed |
| CN-114940683-B | HPK1 inhibitors and uses thereof | 轩竹(北京)医药科技有限公司 | 2023-01-17 | — | — | CN | disclosed |
| EP-4089089-A1 | POLYCYCLIC COMPOUNDS FOR INHIBITING RNA HELICASE DHX33 AND USE THEREOF | Shenzhen Keye Life Technologies, Co., Ltd. (CN) | 2022-11-16 | — | — | EP | disclosed |
| WO-2022127199-A1 | POLYCYCLIC COMPOUNDS FOR INHIBITING RNA HELICASE DHX33 AND USE THEREOF | 深圳开悦生命科技有限公司 | 2022-06-23 | — | — | WO | disclosed |
| WO-2022127199-A1 | POLYCYCLIC COMPOUNDS FOR INHIBITING RNA HELICASE DHX33 AND USE THEREOF | 深圳开悦生命科技有限公司 | 2022-06-23 | — | — | WO | disclosed |
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20110112104-A1 | TRICYCLIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | LES LABORATOIRES SERVIER (FR) | 2011-05-12 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112104-A1 | TRICYCLIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | BAX, CASP3, BCL2 | RAB9A 2092/4885KDM4E 3557/4885ALDH1A1 2604/4885 |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | SAMHD1, POLRMT, NUDT1 | RAB9A 3524/4885KDM4E 1070/4885ALDH1A1 348/4885 |
| US-20230146233-A1 | A CLASS OF POLYCYCLIC COMPOUNDS INHIBITING RNA HELICASE DHX33 AND THE APPLICATION THEREOF | DHX36, DDX21, DDX3X | RAB9A 1473/4885KDM4E 2120/4885ALDH1A1 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.